<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02029885</url>
  </required_header>
  <id_info>
    <org_study_id>KM14-001</org_study_id>
    <nct_id>NCT02029885</nct_id>
  </id_info>
  <brief_title>Sham Controlled Study of Renal Denervation for Subjects With Uncontrolled Hypertension</brief_title>
  <acronym>WAVE_IV</acronym>
  <official_title>Wave IV Study: Phase II Randomized Sham Controlled Study of Renal Denervation for Subjects With Uncontrolled Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kona Medical Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kona Medical Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate that non-invasive renal denervation is safe and shows a net difference in
      blood pressure reduction when compared to sham in subjects with uncontrolled hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a sham controlled, double blind study of subjects with uncontrolled
      hypertension consisting of two arms, sham and therapy. Bilateral renal denervation will be
      performed non-invasively using the Kona Medical Surround Sound System which delivers focused
      ultrasound therapy to ablate the nerves surrounding the renal artery utilizing real time
      ultrasound for targeting and tracking.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety at 6 weeks follow-up</measure>
    <time_frame>6 weeks</time_frame>
    <description>Safety will be assessed by incidence of Major Adverse Events (MAE), defined as a composite of the following events at 6-weeks follow-up.
All cause mortality;
End-stage Renal Disease defined as eGFR &lt; 15 ml/min or need for renal replacement therapy
Hospitalization for hypertensive crisis not related to confirmed non-adherence with medications as assessed by toxicological and other medical analyses and testing.
OR
- New renal artery stenosis &gt; 70% confirmed by angiography within 6 months of randomization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in OBP</measure>
    <time_frame>6 months</time_frame>
    <description>Change in Office Systolic Blood Pressure (OBP) as measured from screening visit one to the 6 month post randomization follow-up visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in ABPM</measure>
    <time_frame>6 months</time_frame>
    <description>Change in average 24-hour ambulatory blood pressure from screening to the 6 month follow-up visit</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Chronic Safety</measure>
    <time_frame>6 months</time_frame>
    <description>Chronic safety is assessed and compared between the control and treatment groups at 6 months post-randomization as follows:
Cardiovascular/Renal Death;
End stage Renal Disease
Increase in serum creatinine of &gt; 50%; and
Hospitalization for hypertensive crisis not confirmed non-adherence with medications.</description>
  </other_outcome>
  <other_outcome>
    <measure>Reduction in blood pressure</measure>
    <time_frame>6 months</time_frame>
    <description>Reduction in systolic and diastolic blood pressure as compared between groups at time points through the 6 month follow-up period for interval differences of 10,15 and 20 mmHg.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of achieving target OBP</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of achieving target OBP (&lt; 140 mmHg) through the 6 month follow-up period.</description>
  </other_outcome>
  <other_outcome>
    <measure>Reduction in anti-hypertensive medications</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of reductions in the number of anti-hypertensive medications and reductions in the doses of anti-hypertensive medications.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in OBP</measure>
    <time_frame>24 months</time_frame>
    <description>Changes in OBP from screening to the 12, 18, and 24 month follow-up periods.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in HR</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in HR (as measured by OBP and ABPM) through the 6 month follow-up period.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Investigational Therapy (Surround Sound)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational Therapy using external focused ultrasound</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Blinded Sham Control Arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Investigational Therapy (Surround Sound)</intervention_name>
    <arm_group_label>Investigational Therapy (Surround Sound)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Control</intervention_name>
    <arm_group_label>Sham Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is at least 18 years of age and no more than 90 years of age

          2. Average SBP ≥ 160 mmHg

          3. 24 hour average ABPM daytime SBP ≥ 135 mmHg.

          4. No medication changes for a minimum of 1 months prior to screening.

          5. At minimum, subject must be on at least three antihypertensive medications, with one
             being a diuretic, and each must meet one or more of the following full dose criteria:

               1. Highest labeled dose according to medication's labeling;

               2. Highest usual dose per clinical guidelines JNC-7;

               3. Highest tolerated dose; and/or

               4. Highest appropriate dose for the subject per the PI's clinical judgment.

          6. Subject has two functioning kidneys.

          7. Subject has an eGFR value of ≥ 30 ml/min/1.73 m² (MDRD formula).

        Exclusion Criteria:

          1. Subject has any secondary cause of hypertension

          2. Subject has evidence of clinically significant renal artery stenosis as determined by
             flow rate, velocity and Doppler analysis on ultrasound

          3. Subject has kidney stones that are of a size and location that are determined at
             discretion of the investigator to potentially interfere with treatment

          4. Subject has a history of intra-abdominal surgery within the past six months

          5. Subject has heterogeneities in the kidney such as large cysts or tumors that are
             determined at discretion of the investigator to potentially interfere with treatment.

          6. Stenotic valvular heart disease for which BP reduction would be hazardous as
             determined by referring physician.

          7. MI, unstable angina, or CVA in the prior 6 months.

          8. Known severe primary pulmonary HTN

          9. Subject has a history of myocardial infarction, unstable angina pectoris, or
             cerebrovascular accident within the last six months.

         10. Subject has hemodynamically significant valvular heart disease.

         11. Subject has BMI over 40 km/m^2

         12. Subject has a target treatment depth over 13 cm.

         13. Subject has anatomy that precludes treatment with the Kona Medical Surround Sound
             System.

         14. Subject is pregnant, nursing, or intends to become pregnant during the trial period.

         15. Subject is currently enrolled in other potentially confounding research.

         16. Subject has any condition that, at the discretion of the investigator, would preclude
             participation in the trial.

         17. Subject is unable, or unwilling, to comply with the protocol-required follow-up
             schedule
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland Schmieder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of University of Erlangen-Nuremberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Omar Dawood</last_name>
    <email>odawood@konamedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Medizinischen Universität Wien -UK für Klinische Pharmakologie</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Wolzt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Angiografia de Occidente, S.A.</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>CHD Cardio Centro de Excelencia SAS</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>St. Anne's University Hospital</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Městská Nomocnice Ostrava</name>
      <address>
        <city>Ostrava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>General University Hospital</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Nemocnice Na Homolee Hospital</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Georg Nickenig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of the University of Erlangen-Nuremberg</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Thuemmler</last_name>
      <email>sabine.thuemmler@uk-erlangen.de</email>
    </contact>
    <investigator>
      <last_name>Roland Schmieder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CardioVascular Center Frankfurt - Sankt Katharinen Hospital</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Horst Sievert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Wenzel Oberarzt, MD</last_name>
      <phone>+49(40) 7410-50026</phone>
      <email>wenzel@uke.de</email>
    </contact>
    <investigator>
      <last_name>Ulrich Wenzel Oberarzt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniklinik Köln</name>
      <address>
        <city>Koln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatjana Schewior</last_name>
      <phone>+49 (221) 478 88273</phone>
      <email>tatjana.schewior@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Hannes Reuter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ursula Banning-Eichenseer</last_name>
      <phone>+49 341 9720657</phone>
      <email>ursula.banning-eichenseer@med.uni-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Dierk Scheinert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sana CardioMed Nord</name>
      <address>
        <city>Luebeck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anke Constantz</last_name>
      <phone>+49 451 585 1951</phone>
      <email>anke.constantz@sana.de</email>
    </contact>
    <investigator>
      <last_name>Joachim Weil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Muenchen</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilka Ott, MD</last_name>
      <phone>+49 (89) 1218-4578</phone>
      <email>ott@dhm.mhn.de</email>
    </contact>
    <investigator>
      <last_name>Ilka Ott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clemens Hospital GmbH</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter Baumgart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Angiography</name>
      <address>
        <city>Aukland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oddział Kliniczny II Kliniki Kardiologii</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dariusz Dudek, MD</last_name>
      <phone>+48 12 42 47 181</phone>
      <email>mcdudek@cyfronet.pl</email>
    </contact>
    <investigator>
      <last_name>Dariusz Dudek, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute Of Cardiology</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Witkowski, MD</last_name>
      <phone>+48 22 34 34 127</phone>
      <email>witkowski@hbz.pl</email>
    </contact>
    <investigator>
      <last_name>Adam Witkowski, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Indranil Desgupta, MD, DM, FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Wales</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Coulson, MD</last_name>
      <phone>+44 (0) 7968 366691</phone>
      <email>coulsonjm@cardiff.ac.uk</email>
    </contact>
    <investigator>
      <last_name>James Coulson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Sharp, MD</last_name>
      <email>andrew.sharp5@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Andrew Sharp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Glasgow</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alan Jardine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mel Lobo, PhD</last_name>
      <phone>+44 (0) 7780 700440</phone>
      <email>m.d.lobo@qmul.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Mel Lobo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Southampton University Hospital</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Wilkinson</last_name>
      <phone>+44 (0) 7931 703058</phone>
      <email>james.wilkinson@uhs.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>James Wilkinson, PhD FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2014</study_first_submitted>
  <study_first_submitted_qc>January 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2014</study_first_posted>
  <last_update_submitted>January 6, 2016</last_update_submitted>
  <last_update_submitted_qc>January 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Renal Denervation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

